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ABSTRACT
Background: Nonvariceal upper gastrointestinal bleeding 
emerges as a major complication of using antiplatelet agents and/
or anticoagulants and represents a clinical challenge in patients 
undergoing these therapies.
Aim: To characterize patients with nonvariceal upper gastroin-
testinal bleeding related to antithrombotics and their management, 
and to determine clinical predictors of adverse outcomes.
Methods: Retrospective cohort of adults who underwent upper 
gastrointestinal endoscopy after nonvariceal upper gastrointesti-
nal bleeding from 2010 to 2012. The outcomes were compared 
between patients exposed and not exposed to antithrombotics.
Results: Five hundred and forty-eight patients with nonvariceal 
upper gastrointestinal bleeding (67% men; mean age 66.5 ± 16.4 
years) were included, of which 43% received antithrombotics. Most 
patients had comorbidities. Peptic ulcer was the main diagnosis and 
endoscopic therapy was performed in 46% of cases. The 30-day 
mortality rate was 7.7% (n = 42), and 36% were bleeding-relat-
ed. The recurrence rate was 9% and 14% of patients with initial 
endoscopic treatment needed endoscopic retreatment. There were 
no significant differences between the exposed and non-exposed 
groups in most outcomes. Co-morbidities, hemodynamic instabil-
ity, high Rockall score, low hemoglobin (7.76 ± 2.72 g/dL) and 
higher international normalized ratio (1.63 ± 1.13) were associated 
significantly with mortality in a univariate analysis.
Conclusions: Adverse outcomes were not associated with 
antithrombotic use. The management of nonvariceal upper gas-
trointestinal bleeding constitutes a challenge to clinical performance 
optimization and clinical cooperation.
Key words: Anticoagulants. Comorbidity. Endoscopy. Gastroin-
testinal. Gastrointestinal hemorrhage. Outcome assessment. Plate-
let aggregation inhibitors.
INTRODUCTION
Nonvariceal upper gastrointestinal bleeding (NVUGB), 
a relevant clinical entity in gastroenterology, continues to 
be associated with considerable morbidity and mortality 
and remains a common cause of hospital admission despite 
pharmacological and endoscopic advances (1,2). 
Recently, there have been important changes both in 
available therapeutics and in epidemiological data regard-
ing NVUGB, consistent with an increase in life expectancy 
and the prevalence of chronic diseases (3). Mortality in 
patients with NVUGB seems to be related to comorbidities 
rather than to bleeding events (1), so management of these 
patients requires more than successful hemostasis alone (4).
NVUGB is a major complication of antiplatelet agents 
(APAs) and anticoagulants, and according to the National 
Drug Authority, the use of these agents has been increasing 
in Portugal (5). The risk of NVUGB associated with the 
use of antithrombotics depends on the active substance 
involved, the dose, duration of treatment, indication, and 
therapeutic combinations (double antiplatelet aggregation 
or combination of APAs with anticoagulants) (6). The 
concomitant use of other gastrotoxic agents, including 
nonsteroidal anti-inflammatory drugs (NSAIDs), further 
increases the risk (7). Age, sex, co-morbidities and past 
medical history are other relevant factors to be included 
in risk evaluation (6). Prophylactic co-treatment with pro-
ton pump inhibitors (PPIs) is associated with a marked 
reduction in the risk of NVUGB in patients treated with 
APAs (while this protective ability does not seem to apply 
to anticoagulants) and should be considered when there 
is a high hemorrhagic risk (8,9). Patients treated with 
antithrombotics with major NVUGB have a high risk of 
persistence or bleeding recurrence with prolonged use of 
these agents. However, the optimal duration of treatment 
discontinuation remains to be defined, as does the best 
method for reversing hypocoagulation and whether treat-
ment discontinuation should be complete or partial, given 
the thromboembolic risk (6). In this context, healthcare 
professionals deal with a permanent and dynamic risk-ben-
efit assessment from diagnosis to therapy. In Portugal, data 
regarding the impact of this topic are scarce. 
The aims of this study are to assess the magnitude of 
NVUGB associated with the use of APAs and/or anticoag-
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ulants and to define clinical predictors of adverse outcomes 
that will enable better risk stratification and clinical man-
agement of this particular population.
MATERIAL AND METHODS
Type of study and selection criteria
From January 2010 to December 2012, all adult patients referred 
to the gastroenterology service of a Portuguese hospital for NVUGB 
(whether from the emergency room, hospital ward [for other rea-
sons] or via transfer from other hospital units) were included in 
this observational retrospective cohort study. Data collected from 
medical and endoscopic records was used. The study was approved 
by the institution’s ethics committee.
NVUGB cases were defined by the presence of hematemesis, 
melena, hematochezia, and/or other clinical or laboratory evidence 
of blood loss in the upper gastrointestinal tract confirmed by upper 
gastrointestinal endoscopy (UGE). Exclusion criteria included 
absence of NVUGB in endoscopy and incomplete records. Patient 
selection is summarized in figure 1. 
Variables
Recorded data included: age, sex, form of presentation of NVUGB, 
hemodynamic (heart rate and blood pressure) and analytic (hemo-
globin and international normalized ratio [INR]) parameters, cause 
of NVUGB according to UGE, type of endoscopic treatment per-
formed, timing of UGE, comorbidities and the patient’s usual medica-
tion (APAs, anticoagulants, NSAIDs, PPIs), Rockall score, number of 
days of hospitalization and units of red blood cells (RBC) transfused, 
need for surgery or endoscopic retreatment, 30-day rebleeding, 30-day 
mortality, and cause of death (nosocomial complications, failure to 
control bleeding, comorbidities or treatment complications).
Statistical analysis
The SPSS software (version 22) was used to perform statistical analy-
sis. Results are presented as mean ± standard deviation (SD) or mean and 
minimum-maximum values  for continuous variables and as absolute (n) 
and relative (%) frequencies for categorical variables. The level of statis-
tical significance considered was p < 0.05. A Chi-squared test or Fisher’s 
exact test (when appropriate) were used to study the relationship between 
categorical variables. For continuous variables, normal distribution was 
evaluated first and Student’s t-test or Mann-Whitney test were applied 
when appropriate. Binary logistic regression was used for multivariate 
analysis, including variables in univariate analysis with p < 0.05.
RESULTS
Patient characteristics
A total of 548 patients were included. Baseline demograph-
ic and clinical characteristics are listed in table I. The mean 
age of the exposed group (72.84 ± 11.97) was significantly 
higher than that of the unexposed group (61.87 ± 17.58).
Medication used by patients
The distribution of NVUGB episodes by different 
antithrombotic exposure regimens is represented in fig-
ure 2. The most commonly used drug was acetylsalicylic 
acid (ASA) 100 mg (36.5%). We found that 20.8% of all 
patients and 21.5% of the exposed group were taking PPIs, 
without significant differences between exposed and unex-
posed patients, and that 20.1% used NSAIDs, of which 
32.7% were taking APAs, 11.8% anticoagulants and 18.2% 
a PPI simultaneously.
Characterization of NVUGB
Patients with NVUGB mainly presented with hemate-
mesis (56.6%) or melena (51.8%). In relation to the hemo-
dynamic status, the majority of patients (55.5%) were sta-
ble at presentation and 7.5% were admitted with systolic 
blood pressure (SBP) < 90 mmHg. In the group of unstable 
patients, 43.9% took antithrombotics. There were no sig-
nificant differences in hemodynamic status between the 
exposed and unexposed (p = 0.571) groups.
With regard to analytic parameters, the mean hemo-
globin value at presentation was 8.96 ± 3.91 g/dL and 
INR 1.36 ± 1.02. There were no significant differences 
between the exposed and non-exposed groups in relation to 
the hemoglobin level, but the INR value was significantly 
higher in the exposed group (1.65 ± 1.43; p = 0,001).
Approach to NVUGB  
UGE was performed within the first 6 hours (inclusive) 
in 37.9% of the patients and after 24 hours in 9.6% (this 
Fig 1. Study population selection. Exposed group: patients using APAs 
and/or anticoagulants.
NVUGB episodes (n = 651)
Recurrences (n = 7)
NVUGB episodes with 
incomplete records  
(n = 96)
NVUGB episodes that satisfy 
inclusion criteria (n = 555)
Exposed group 
(n = 233)
Non-exposed 
group (n = 315)
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estimate was not calculated in 4 patients due to insuffi-
cient information). Of the patients studied, 45.6% under-
went endoscopic treatment with no statistically significant 
differences between the exposed and unexposed groups. 
The most commonly used endoscopic treatment was drug 
injection (89.6%). Endoscopic retreatment was necessary 
in 6.4%. Peptic ulcer (PU) emerged as the main diagno-
sis, 26.5% were gastric ulcers and 24.6% were duodenal 
ulcers. In this sample, 46.4% had a high Forrest classifi-
cation (Ia, Ib, IIa) with no significant differences between 
exposed and unexposed patients (p = 0.518), or between 
those who were and were not on PPIs (p = 0.933). The 
average Rockall score was intermediate-high risk (4.98 ± 
2.02) with significant differences between exposed (higher 
Rockall score) and unexposed patients (p < 0.001).
Outcome
The main outcomes of our cohort are listed in table II. 
Statistically significant differences were observed in length 
of hospital stay among patients who were receiving concom-
itant APAs and anticoagulants vs those who did not (10.52 
[0-59] vs 6.32 [0-191] days, respectively; [p = 0.0014]).
The need for surgery as treatment for NVUGB was 
recorded in 3.8% patients with significant differences (p 
= 0.037) between hemodynamically stable and unstable 
patients (5.7% of the unstable patients required urgent sur-
gery vs 2.3% of stable patients) and between patients with 
(9.4%) and without (2.7%) Forrest lesions classified as 
“high risk” (p = 0.018).
With regard to the patients who underwent endoscopic 
retreatment, there was a positive relationship with the need 
for urgent surgery (p = 0.008), lower hemoglobin values (p 
= 0.015) (7.78 ± 2.62 vs 9.05 ± 3.98) and higher Rockall 
scores (p = 0.005) (with endoscopic retreatment: Rockall 
score 5.89 ± 1.62; without retreatment, 4.91 ± 2.03).
Rebleeding was significantly related with the need for 
endoscopic retreatment (31.4% with recurrence vs 3.8% 
without; [p < 0.001]), a greater duration of hospitaliza-
tion (10.41 [0-61] vs 6.18 [0-191]) and transfused RBC 
units (4.25 [0-23] vs 2.20 [0-18]). Thirty-day mortality (p 
= 0.061) and need for urgent surgery (p = 0.053) were 
found to occur less frequently in patients who underwent 
UGE within the first 24 hours (exclusive) compared to 
those who underwent UGE after 24 hours (inclusive) 
(6.9% mortality rate and 3.3% rate of surgeries vs 14.3% 
and 8.9%, respectively), which almost reached statistical 
significance. Time to UGE ≥ 24 h was significantly related 
with longer hospital stays (8.34 [0-48] vs 6.37 [0-191]; p 
= 0.033) and more RBC units transfused (3.82 [0-23] vs 
2.23 [0-18]; p < 0.001).
Table I. Baseline patient characteristics (demographic and clinical)
Global (n = 548) Exposed (E) (n = 233) Non-exposed (NE) (n = 315) E/NE P value
Age (years) - Mean ± standard deviation (SD) 66.53 ± 16.36 72.84 ± 11.97 61.87 ± 17.58 < 0.001
Male (%) 67% 63.5% 69.5% NS
Co-morbidities (%) 81.6% 96.6% 70.5% < 0.001
 Heart disease 31.6% 51.9% 16.5% < 0.001
 Kidney disease 11.3% 16.7% 7.3% 0.001
 Hematological disease 1.5% 0% 2.5% 0.024
 Neoplastic disease 13.1% 12% 14% NS
 Metastatic disease 3.6% 2.6% 4.4% NS
 Liver disease 12.8% 3.9% 19.4% < 0.001
 Vascular disease 7.3% 12% 3.8% < 0.001
 Cerebrovascular disease 11.5% 24.9% 1.6% < 0.001
 High blood pressure 45.6% 65.7% 30.8% < 0.001
 Diabetes mellitus 24.6% 36.5% 15.9% < 0.001
 Transplant 1.8% 0.4% 2.9% 0.05
 Previous history of PU/gastritis/NVUGB 14.1% 9.9% 17.1% 0.015
NS: Not significant.
Fig 2. Distribution of NVUGB episodes according to different antithrom-
botic exposure regimens.
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In the multivariate analysis, the risk of 30-day mortality 
was found to be about five times higher in patients with 
one or more comorbidities (95% confidence interval [CI]: 
1.18 to 20.98). Metastatic disease was associated with a 
twelvefold increase in the risk of death (odds ratio [OR] 
= 12.27; 95% CI: 4.75 to 31.70). Other factors that were 
significantly associated with mortality were high Rockall 
score, lower hemoglobin (7.76 ± 2.72 vs 9.06 ± 3.98 g/dL) 
and higher INR (1.63 ± 1.13 vs 1.34 ± 1.00).
DISCUSSION
This study allowed us to characterize NVUGB asso-
ciated with the use of APAs and/or anticoagulants in a 
Portuguese population and to better understand the com-
plexity of these patients, the clinical entity and the medical 
approach undertaken, and to identify major factors which 
impact on short-term results. To the best of our knowledge, 
this is the first study in Portugal that aims to specifically 
assess the impact of the consumption of antithrombotics 
in patients with NVUGB.
According to A. Lanas et al., the NVUGB relative risk 
is about 1.55 times higher with low-dose ASAs compared 
to non-use whereas when used in combination with clopi-
dogrel or anticoagulants this increased the risk (OR = 1.86 
and OR = 1.93, respectively) (10). The results of our study 
show that 1 in every 2 to 3 patients with NVUGB were 
on APAs and/or anticoagulants, a higher proportion than 
observed (1 in 4) in a similar study conducted in Spain 
between 2004 and 2007 by P. Wikman-Jorgensen et al. 
(11). This difference may be due to the fact that the inclu-
sion criteria were different, as they excluded patients who 
used NSAIDs rather than ASAs, or it may reflect a glob-
al trend in increased antithrombotic prescription (12-14) 
accompanied by an increased prevalence of diseases for 
which this therapy is recommended.
The characteristics of the patients with NVUGB in the 
present study represent the demographic evolution of mod-
ern society: the vast majority were over 65 years old and 
had one or more comorbidities. 
With regard to the evaluated outcomes, it was found that 
exposure to antithrombotics had no significant impact on 
30-day mortality nor on the need for endoscopic retreat-
ment or urgent surgery. Regarding the 30-day relapse rate, 
it was found that the exposed group appeared to be pro-
tected, since a higher percentage of non-exposed patients 
(11.4% vs 6.4%) showed a new episode of NVUGB after 
effective hemostasis with a statistically significant differ-
ence. These findings are in agreement with T. Solakoglu 
et al., who have put forth the use of longer duration PPI 
infusion in the exposed group as a possible explanation. It 
was recognized that an appropriate duration of this therapy 
was essential to allow for the healing of the gastrointesti-
nal mucosa and to prevent recurrence in high-risk patients 
(15). Another possible explanation could be the greater 
prophylactic use of PPIs in the exposed group (21.5% vs 
20.3%); however, a lack of statistical significance makes 
this a less likely hypothesis.
The recurrence rate was also significantly related with lon-
ger hospital stay, the need for endoscopic retreatment, and 
more RBC transfusions, with the subsequent costs involved.
According to evidence currently available, the use of 
intravenous PPIs reduces relapse rates and the need for 
endoscopic retreatment and surgery (16-18). The most 
recent recommendations suggest using a high initial dose 
of 80 mg in bolus followed by continuous infusion of 8 
mg/h for 3 days, since the majority of relapses occur during 
this period (14,19,20). The benefit of PPI use after endo-
scopic hemostasis for mortality was observed in patients 
with active bleeding or visible vessels (16,19,21,22). After 
intravenous therapy with a PPI, an oral prescription of a 
single daily dose is suitable for a period of time determined 
by the etiology of the NVUGB (18,19,22).
Table II. Clinical outcome
Global (n = 548) E (n = 233) NE (n = 315) E/NE p value
Recurrence ≤ 30 days, n (%) 51 (9.3%) 15 (6.4%) 36 (11.4%) 0.047
Mortality ≤ 30 days, n (%) 42 (7.7%) 16 (6.9%) 26 (8.3%) NS
Failure to control bleeding 12 (2.2%) 3 (1.3%) 9 (2.9%)
Treatment complications 3 (0.5%) 3 (1.3%) 0 (0%)
Co-morbidities 23 (4.2%) 9 (3.9%) 14 (4.4%)
Nosocomial complications 4 (0.7%) 1 (0.4%) 3 (1%)
Death attributable to NVUGB episode, n (%) 15 (2.7%) 6 (2.6%) 9 (2.9%) NS
Endoscopic retreatment, n (%) 35 (6.4%) 11 (4.7%) 24 (7.6%) NS
Urgent surgery, n (%) 21 (3.8%) 7 (3%) 14 (4.4%) NS
Hospital stay, mean number of days (min-max) 6.57 (0-191) 7.13 (0-191) 6.15 (0-81) NS
RBC, mean (min-max) 2.39 (0-23) 2.51 (0-18) 2.31 (0-23) 0.015
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The present study did not evaluate the use of PPIs after 
UGE. However, according to the existing data in the Portu-
guese population, PPIs are used on almost all patients, but 
perfusion rates are lower than desirable taking all poten-
tially eligible patients into account (3,23). Thus, there 
seems to be room for the optimization of acid secretion 
suppression in addition to endoscopic hemostasis, which 
may result in lower relapse rates.
The mortality rate associated with NVUGB has 
remained virtually unchanged at between 5% and 10% (14) 
in spite of advances in treatment that, according to recent 
research, have been associated with the fact that the major-
ity of these deaths are related to non-bleeding causes (4). 
This information is consistent with the results of our study, 
since the cause of death was not attributable to NVUGB in 
64.3% of cases. Another retrospective, multicentre study in 
Portugal registered a 4.8% mortality rate, 83.3% of which 
were not attributed to NVUGB (3). Recent data confirm 
that in these cases, mortality is related primarily to patient 
comorbidities (3,24), which is consistent with the results 
of this sample. Thus, attempts to decrease mortality rates 
need to extend beyond the effective control of hemorrhage, 
with particular strengthening of supportive treatment and 
prevention of complications in other organs (4). Reinforc-
ing these findings, we identified other factors that were 
significantly correlated with mortality: high Rockall score, 
hemodynamic instability, lower hemoglobin values (7.76 
± 2.72 g/dL) and higher INR (1.63 ± 1.13).
However, in some cases, the outcome can hardly be 
improved, since the bleeding episode is a terminal event of 
other underlying disease conditions, including metastatic 
neoplasm or multiple organ failure (4).
With regard to the timing of UGE, this series found that 
its implementation within the first 24 hours was associated 
with better outcome, in agreement with some recent studies 
(19,25). However, although it seems intuitive that earlier 
UGE would be associated with the best results, the ten-
dency observed was that no benefits were seen when per-
formed within the first 12 hours with regard to reduction 
of recurrence, death, and the need for surgery (25,26). This 
can be justified by the fact that when UGE is performed 
earlier in the active bleeding period, a large amount of 
blood and existing clots not only obscure the source of 
bleeding, but also complicate achieving endoscopic hemo-
stasis (27).
One of the problems that often arise in clinical prac-
tice and which led to the planning of this study is how 
to control and prevent NVUGB relapse in patients being 
treated with APAs and/or anticoagulation. First, it is rec-
ognized that maintenance of this therapy increases the risk 
of recurrence or the continuation of bleeding; however, 
these patients have an increased thromboembolic risk due 
to the underlying disease. Temporary discontinuation of 
antithrombotic therapy is often necessary to control the 
bleeding and to prevent an early relapse (15). According 
to current evidence, the use of APAs as a secondary pro-
phylaxis should be reinitiated as soon as possible after the 
episode of NVUGB (28), even if this would increase the 
rebleeding rate as it can potentially reduce overall mortal-
ity (29) and its discontinuation increases the risk of death 
and acute cardiovascular events by around sevenfold (30). 
In these cases, the protective effect of APAs exceeds their 
potential gastrotoxic effects. With regard to anticoagula-
tion, the decision to withdraw or restart anticoagulants 
should be considered on an individual basis. In relation to 
traditional anticoagulants, it has been verified that throm-
bosis and mortality decrease without a significant increase 
of relapse in cases where anticoagulation is reinitiated 
within 90 days of the NVUGB episode (31). 
According to current recommendations, in addition to 
acid suppression with PPIs after an episode of NVUGB, 
all patients with PU should also be tested for the presence 
of Helicobacter pylori, and positive cases should undergo 
eradication therapy (22,25).
One of the strengths of this study is that it was an 
observational study, which allowed us to evaluate out-
comes more reliably since they are representative of the 
“real clinical practice” without intervention. Furthermore, 
although this study was conducted in only one central 
Portuguese hospital, the gastroenterology service of this 
hospital serves as a regional emergency service at night, 
and receives patients from several hospitals in the north 
who were also included in the study. As a result, this case 
series is representative of a larger group of patients with 
NVUGB. However, because this was a retrospective study, 
the results are dependent upon the quality of the medical 
records obtained. The severity of comorbidities was not 
considered, which could have allowed us to better charac-
terize patients with unfavorable outcomes. Patients were 
not excluded for taking other drugs that could potentially 
increase the risk of NVUGB (non-aspirin NSAIDs, selec-
tive serotonin reuptake inhibitors [32,33] or high-dose cor-
ticosteroids [7]), which may have introduced a bias in the 
results. The duration of treatment was also not taken into 
account, which could have allowed for an estimate to be 
made regarding the exposure time necessary for an episode 
of NVUGB to happen. However, this data was difficult to 
obtain from medical records.
Given that the sample includes inpatients and outpa-
tients, the variable “timing to UGE” likely presents some 
variability. It is expected that this calculation is closer to 
reality in hospitalized patients because it is based on the 
records of healthcare professionals, while it may be less 
reliable in outpatient cases since the time interval between 
the NVUGB episode and admission is uncertain.
The results of this study support the current trends found 
in recent studies: NVUGB increasingly occurs in elderly 
populations with several comorbidities; adverse outcomes 
are less associated with iatrogenic causes such as the use of 
APAs and/or anticoagulants. Although the risk of NVUGB 
is increased in patients exposed to these drugs, there are 
some measures that can decrease the incidence of bleeding 
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and that can be optimized in our population. After an epi-
sode of NVUGB, the medical approach needs to assume 
a broader spectrum: in addition to an efficient endoscopic 
hemostasis, the implementation of special care to suit the 
clinical characteristics of patients, including their comor-
bidities (the leading cause of death in this context), is fun-
damental.
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